The results demonstrated that, at various effector to targets (E/T) ratios, CD155 CAR-T cells effectively eliminated CD155+ MOLM13, U937, and THP-1 cell lines, compared with mock T cells, whereas CD155 CAR-T cells showed no cytotoxicity toward the same AML cell lines having undergone genetic disruption of CD155 (CD155-KO). This evidence concerns the gene PVR and acute myeloid leukemia.